Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Cogent Biosciences, Inc. is experiencing significant momentum entering 2026, driven by multiple regulatory catalysts and positive trial results for its lead product, bezuclastinib, targeting genetically defined diseases [2] Recent Company Highlights - The SUMMIT NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) was submitted in December 2025, with the APEX NDA submission for patients with Advanced Systemic Mastocytosis (AdvSM) on track for the first half of 2026 [4] - The PEAK NDA for bezuclastinib in patients with second-line Gastrointestinal Stromal Tumors (GIST) has been initiated under the FDA's Real-Time Oncology Review (RTOR) program, with completion expected by April 2026 [4] - Six abstracts from the SUMMIT trial have been accepted for presentation at the 2026 AAAAI annual meeting, highlighting the clinical benefits of bezuclastinib [5] Financial Position - As of December 31, 2025, Cogent had cash, cash equivalents, and marketable securities totaling $900.8 million, sufficient to fund operations into 2028 [4][22] - Research and development expenses for Q4 2025 were $75.6 million, up from $62.0 million in Q4 2024, driven by ongoing pivotal trials and NDA filings [12] - General and administrative expenses for Q4 2025 were $23.9 million, compared to $11.7 million in Q4 2024, reflecting organizational growth and preparations for the commercial launch of bezuclastinib [13] Clinical Trial Results - The SUMMIT trial demonstrated clear clinical benefits across all symptom domains in NonAdvSM patients, with significant improvements in 11 individual symptoms and a reduction in serum tryptase levels [5] - The APEX trial reported an objective response rate of 57% per mIWG criteria and 80% per PPR criteria, with 89% of patients achieving a ≥50% reduction in bone marrow mast cells [5] Upcoming Milestones - The company plans to submit the APEX NDA in the first half of 2026 and complete the PEAK NDA submission by April 2026 [9] - Detailed clinical data from the PEAK and APEX trials will be presented at major medical meetings during the first half of 2026 [9]